LIWANLI Innovation Co Ltd - Asset Resilience Ratio
LIWANLI Innovation Co Ltd (3054) has an Asset Resilience Ratio of 12.97% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does LIWANLI Innovation Co Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how LIWANLI Innovation Co Ltd's Asset Resilience Ratio has changed over time. See what is LIWANLI Innovation Co Ltd's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down LIWANLI Innovation Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of LIWANLI Innovation Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$100.63 Million | 12.97% |
| Total Liquid Assets | NT$100.63 Million | 12.97% |
Asset Resilience Insights
- Moderate Liquidity: LIWANLI Innovation Co Ltd has 12.97% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
LIWANLI Innovation Co Ltd Industry Peers by Asset Resilience Ratio
Compare LIWANLI Innovation Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for LIWANLI Innovation Co Ltd (2003–2024)
The table below shows the annual Asset Resilience Ratio data for LIWANLI Innovation Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.30% | NT$89.50 Million ≈ $2.82 Million |
NT$792.19 Million ≈ $24.96 Million |
-1.86pp |
| 2023-12-31 | 13.16% | NT$109.75 Million ≈ $3.46 Million |
NT$834.17 Million ≈ $26.28 Million |
+2.07pp |
| 2022-12-31 | 11.09% | NT$89.35 Million ≈ $2.82 Million |
NT$805.93 Million ≈ $25.39 Million |
-20.02pp |
| 2021-12-31 | 31.11% | NT$294.88 Million ≈ $9.29 Million |
NT$947.90 Million ≈ $29.86 Million |
+18.46pp |
| 2020-12-31 | 12.65% | NT$126.93 Million ≈ $4.00 Million |
NT$1.00 Billion ≈ $31.61 Million |
-0.92pp |
| 2019-12-31 | 13.57% | NT$153.91 Million ≈ $4.85 Million |
NT$1.13 Billion ≈ $35.73 Million |
+1.48pp |
| 2018-12-31 | 12.10% | NT$128.45 Million ≈ $4.05 Million |
NT$1.06 Billion ≈ $33.45 Million |
+7.35pp |
| 2017-12-31 | 4.74% | NT$76.14 Million ≈ $2.40 Million |
NT$1.61 Billion ≈ $50.59 Million |
-15.43pp |
| 2016-12-31 | 20.17% | NT$350.08 Million ≈ $11.03 Million |
NT$1.74 Billion ≈ $54.68 Million |
+2.91pp |
| 2015-12-31 | 17.26% | NT$286.37 Million ≈ $9.02 Million |
NT$1.66 Billion ≈ $52.26 Million |
+3.08pp |
| 2014-12-31 | 14.18% | NT$271.65 Million ≈ $8.56 Million |
NT$1.92 Billion ≈ $60.37 Million |
+8.28pp |
| 2013-12-31 | 5.90% | NT$126.36 Million ≈ $3.98 Million |
NT$2.14 Billion ≈ $67.49 Million |
+0.24pp |
| 2012-12-31 | 5.66% | NT$83.87 Million ≈ $2.64 Million |
NT$1.48 Billion ≈ $46.70 Million |
-2.06pp |
| 2011-12-31 | 7.72% | NT$95.32 Million ≈ $3.00 Million |
NT$1.24 Billion ≈ $38.92 Million |
-26.50pp |
| 2009-12-31 | 34.21% | NT$422.14 Million ≈ $13.30 Million |
NT$1.23 Billion ≈ $38.88 Million |
+26.17pp |
| 2008-12-31 | 8.04% | NT$62.78 Million ≈ $1.98 Million |
NT$781.16 Million ≈ $24.61 Million |
+3.11pp |
| 2007-12-31 | 4.92% | NT$36.46 Million ≈ $1.15 Million |
NT$740.41 Million ≈ $23.33 Million |
+4.47pp |
| 2005-12-31 | 0.45% | NT$2.41 Million ≈ $75.90K |
NT$533.37 Million ≈ $16.80 Million |
-4.63pp |
| 2004-12-31 | 5.08% | NT$48.95 Million ≈ $1.54 Million |
NT$963.72 Million ≈ $30.36 Million |
-8.87pp |
| 2003-12-31 | 13.95% | NT$174.46 Million ≈ $5.50 Million |
NT$1.25 Billion ≈ $39.41 Million |
-- |
About LIWANLI Innovation Co Ltd
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for male, female, elderly, and children. Its products include anti-aging desire, pro-active nutrients capsules, black elderberry powder, probiotic enzymes, oral care tablets, resveratrol red grape extract, algae DHA soft gels, shea butte… Read more